Page 7 - mCSPC EN Booklet-Feb 2021 Web

Introduction

Over the last five years, recent clinical trials have revealed life-extending therapies
and expanded the treatment options for patients with metastatic castration-naïve/
castration-sensitive prostate cancer (mCNPC/mCSPC). Stratification of patients by
disease volume and risk status in some of these trials has implications for clinical
management. In response to these advancements, The Canadian Urologic Oncology
Group (CUOG), with the Canadian Urological Association (CUA), published a practice
guideline (So AI, et al. Can Urol Assoc J. 2020;14(2):17-23) in February 2020 to help
optimize clinical care in this group of patients.

This handbook, Practical Approaches to Managing Castration-Naïve and Castration-
Sensitive Prostate Cancer, aligns with the recently published guidelines. It is intended
to provide a concise overview of the practical aspects of patient management
throughout the treatment continuum, including patient assessment, treatment
options, monitoring and toxicity management. The information presented in this
handbook is not definitive guidance but rather is meant to support discussions with
the patient and multidisciplinary team regarding both short- and long-term treatment
planning and patient management.

The Health Canada approval status of agents mentioned in this handbook reflects
the products’ indicated uses at the time of publishing. Please consult individual
Product Monographs (through the Health Canada Drug Product Database) for the
most current indicated uses. The Canadian Urological Association aims to update the
content as the treatment landscape changes and new agents become available.
We welcome your feedback to ensure this handbook serves as a helpful resource
in your practice.

Practical Approaches to Managing mCNPC and mCSPC 5